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Latest estimates indicate that nutritional deficiencies account for 3 million child deaths each year in less-developed
countries. Targeted nutritional interventions could therefore save millions of lives. However, such interventions
require careful optimization to maximize benefit and avoid harm. Progress toward designing effective life-saving interventions is currently hampered by some serious gaps in our understanding of nutrient metabolism in humans. In this
Personal Perspective, we highlight some of these gaps and make some proposals as to how improved research methods
and technologies can be brought to bear on the problems of undernourished children in the developing world.
Introduction
Malnutrition, in its various guises, represents the greatest modifiable threat to global health and survival. This is especially so
among children in the poorest nations of the world, where malnutrition and infections act hand in hand to create a self-reinforcing downward cycle of tissue depletion and lowered resistance
to disease. Many of the solutions are already known and require
political will, economic advancement, and operational research to
achieve a resolution. In the interim, many international agencies
are focusing attention on combating micronutrient deficiencies
that lead to so-called “hidden hunger,” since these are potentially
amenable to short-term resolution. However, there remain a host
of unsolved scientific questions that critically inhibit the development of such interventions that could potentially bring immediate
health benefits and save millions of lives.
Space limitations preclude an exhaustive overview of the
unknowns in the field. Instead, we present here a selective outline of some key research gaps, first emphasizing the global
burden of childhood malnutrition. This discussion and a series
of case studies of some unsolved nutritional issues serve as the
foundation for proposing several challenges to the research
community that, if overcome, we believe will lead to the development of interventions to combat nutrient deficiencies (see
The challenges). We also hope that by posing here the challenges
to overcoming a severe, but modifiable, problem of developing
countries, we might help to create fresh momentum for the idea
that advanced technologies and innovative approaches could
help solve this age-old problem.
The global burden of childhood malnutrition
Childhood undernutrition is highly prevalent in low- and middleincome countries. Of all children born alive in such countries, 11%
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have suffered from intrauterine growth restriction (1). Wasting (a
measure of acute malnutrition detected as a low weight-for-height)
affects 10% of these children, or about 55 million individuals (1).
Stunting (a measure of chronic malnutrition detected as a low
height-for-age) is an even larger problem, affecting 31% of children
in low- and middle-income countries — approximately 170 million
individuals worldwide (1). Being underweight (low weight-for-age)
can result from stunting, wasting, or both and is used by the UN as
an indicator of progress toward its first Millennium Development
Goal: to eradicate extreme poverty and hunger by 2015 (http://
www.un.org/millenniumgoals/). Globally, the proportion of children who are underweight declined modestly from 33% in 1990 to
27% in 2005. However, slow progress in South Asia and sub-Saharan Africa forecasts that the first Millennium Development Goal
will not be reached (2).
A recent analysis by the Maternal and Child Undernutrition
Study Group (3) estimated that stunting, severe wasting, and
intrauterine growth restriction together were responsible for 2.2
million deaths annually and 21% of disability-adjusted life years
(DALYs), which are defined as the sum of the years of life lost due
to premature mortality and the years of health and productivity
lost due to disability for children younger than 5 years. Deficiencies of vitamin A and zinc were estimated to be responsible for
0.6 and 0.4 million deaths, respectively, and a combined 9% of
global childhood DALYs. Iron and iodine deficiencies resulted in
few child deaths, and combined were responsible for about 0.2%
of global childhood DALYs. Iron deficiency as a risk factor for
maternal mortality added 115,000 deaths and 0.4% of global total
DALYs. Suboptimum breastfeeding was estimated to be responsible for 1.4 million child deaths each year and 10% of DALYs in
children younger than 5 years. In an analysis that accounted for
coexposure of these nutrition-related factors, they were together
responsible for about 35% of child deaths and 11% of the total
global disease burden (3). Undernourished children who survive to
adulthood tend to have lower human capital, lower school achievement, reduced economic productivity, shorter adult height, and,
for women, offspring with lower birth weight (4). To make things
worse, children who suffered undernutrition in utero or in the first
years of life, and who later gain weight rapidly — a common condi-
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The challenges
Challenge 1: To identify better and more comprehensive biomarkers of nutrient status in humans, as well as economic and accurate ways of measuring them.
Challenge 2: To expand the knowledge base with respect to host-pathogen competition for essential nutrients.
Challenge 3: To introduce additional rigor and sophistication into studies of the relationships between nutrient status and
immune function.
Challenge 4: To emphasize large-scale prospective studies of nutritional contributors to infectious disease susceptibility, rather
than post-hoc association studies.
Challenge 5: To characterize the significance of the human gut microbiome in modulating nutritional status, with a view to developing novel biomarkers of nutrient status and interventions based on manipulating the microbiota.
Challenge 6: To build the capacity to more rapidly translate basic discoveries related to the interrelationships between nutrient
processing and metabolism, and variations in our human (and microbial) genomes, transcriptomes, proteomes, and metabolomes, into preventative and therapeutic interventions for children in the poorest nations of the world.

tion in middle-income and emerging countries — are at particular
risk of chronic cardiovascular and metabolic diseases (5).
Every year, more than $70 billion are spent on health research
and development by the public and private sectors. An estimated
10% of this sum is used for research into 90% of the global burden
of disease, leading to the so-called “10/90 gap” (6). In particular,
the size of the research effort on nutritional topics is clearly insufficient to address a problem responsible for 10%–20% of all lost
DALYs globally (Figure 1).
The complexities of nutritional metabolism
There are approximately 40 known essential nutrients. Each has
generated a huge research literature, and when the potential interplay between nutrients is taken into consideration, the problem
of defining their myriad effects on human physiology becomes
apparent. In more recent years, attention has also focused on a
large range of food-derived phytochemicals with diverse physiological roles whose health-protective effects have only recently started
to emerge. These are just the biochemical complexities. There are
also interactions between host genotype, diet, behavior, and social
factors that ultimately govern diet-related disease patterns.
Zinc provides one example of some of the challenges involved in
trying to understand diet-disease interactions. In humans, uptake
of zinc from the diet and its subsequent distribution are regulated by a network of 24 known zinc transporter proteins (7). Zinc
finger transcription factors play a key role in regulating our transcriptome, and knowledge of the fundamental role of zinc in gene
replication and expression is advancing rapidly. Nonetheless, no
precise mechanism has been identified by which zinc deficiency,
or toxicity, might determine disease end-points of relevance to a
child living in sub-Saharan Africa. Some randomized control trials in developing countries have shown that zinc supplementation
can reduce morbidity and mortality resulting from diarrhea, pneumonia, and malaria and, in some groups, can enhance growth (8).
However, recent very large randomized placebo control trials in
Nepal and Pemba, each with over 40,000 children enrolled, reported no benefits of zinc supplementation on either morbidity (as
assessed in the Nepal trial) or mortality (as assessed in both trials)
(9, 10). Evidence about the effects of zinc supplementation is therefore equivocal, and because it is based on empirical studies there
remain numerous questions, including: What is the mechanism(s)
of action? What are the optimal dose levels, frequency, and mode?
What is the optimal chemical form of administration? What are
The Journal of Clinical Investigation

the appropriate age groups for treatment? And what diseases are
amenable to such treatment? Moreover, claims that zinc deficiency
plays a critical role in depressed immune function, altered cognitive development, and teratogenesis still have not been conclusively substantiated.
Problems in assessing nutritional status
The design of preventative nutritional interventions optimally
requires a reliable assessment of the micronutrient deficiencies
likely to be suffered in a given area or population. For certain nutrients there are well-defined, clinically detectable sequelae of deficiency (e.g., goiter for iodine deficiency, xerophthalmia for vitamin
A deficiency, and anemia for iron deficiency). These sequelae can
be used as crude indicators of geographic hot spots of deficiency
in resident populations. However, they only detect the extremes
of deficiency, representing the tip of the iceberg of the full health
burden, and for many nutrients no such clinical indicators exist.
As an aid to understanding the nature and consequences of
nutritional deficiencies, Golden proposed a novel system for classifying nutrients as Type I and Type II, according to the body’s
physiological responses to their deprivation (Figure 2) (11). In
response to Type I nutrient deficiency, children’s bodies continue to grow and use up the stored nutrient, eventually leading to tissue depletion, metabolic dysfunction, and consequent
ill health. The illness has characteristic signs and symptoms, so
the deficient nutrient can be identified and remedied. Examples
of some Type I nutrients are iron, ascorbic acid, and vitamin A.
With type II nutrient deficiency, the response is for the body to
stop growing and repairing tissue, in order to conserve the nutrient, or even to break down its own tissues to make the nutrient
available. Other Type II nutrients are lost in the process. No characteristic signs or symptoms differentiate any Type II nutrient
deficiency from another, and detecting deficiency is complex.
It is therefore almost impossible to determine which nutrient
is causing the growth failure. Examples of Type II nutrients are
potassium, magnesium, zinc, and protein.
The conundrum of distinguishing cause from effect in
studies of diet and disease
Interactions between nutritional status and infectious diseases
are bidirectional: certain nutrient deficiencies can promote susceptibility to infection and accelerate disease pathology, whereas
infections lead to deficiencies through suppression of appetite
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Figure 1
Inequity in science budgets in relation to the global burden of childhood
undernutrition. Although more than $70 billion are spent on health
research and development by the public and private sectors each year,
only an estimated 10% of this is used for research into 90% of the
global burden of disease. For example, the amount of money spent
on research into nutritional topics is far exceeded by the extent of the
problem, which is responsible for 10%–20% of all lost DALYs globally.
In these maps, countries are resized according to the prevalence of the
indicator illustrated. Reproduced with permission from Worldmapper
(http://www.worldmapper.org).

compared between subsequent disease cases and disease-free controls using a nested case-control design. There is an urgent need to
apply such designs in less developed nations to identify the critical
antecedent nutritional risk factors in relation to the major killer
diseases: malaria, pneumonia, diarrheal illnesses, tuberculosis
(TB), HIV, and life-threatening protein-energy malnutrition.

and cytokine-induced inhibition of nutrient absorption and tissue
redistribution. The latter effects, characteristic of the acute phase
response (APR), are generally assumed to be an active, evolutionarily selected part of the orchestrated host defense mechanisms
designed to deprive microorganisms of nutritional substrate. For
example, the APR results in massive changes in iron metabolism,
with inhibition of intestinal absorption and iron release from
hepatocytes and macrophages, resulting in a profound tissue redistribution. Systemic levels of zinc, selenium, retinol, riboflavin, pyridoxine, and ascorbate are also depressed by over 50%, and copper
levels rise (associated with a rise in ceruloplasmin). These changes
greatly confound the interpretation of associations between nutritional status and disease outcomes.
To date, most studies in developing countries have assessed
nutritional status in individuals with existing disease and are thus
very difficult, if not impossible, to interpret. In countries of the
developed world, this problem of establishing direction of causality has been properly addressed in numerous studies of chronic
disease outcomes by using large population groups in whom
dietary, lifestyle, and biochemical assessments made at baseline are

The intersection between host nutrition and
the immune system
Undernourished children are profoundly more likely to die from a
wide range of infections than their better-nourished counterparts
(Figure 3) (12). Despite the widespread recognition of the implications of nutritional deficiencies on immune function, nearly all
human studies have focused more on quantifying nutritional status than on dissecting the putatively associated immune responses.
This reflects, in part, the difficulty of doing detailed functional
immune assays in remote environments. For example, the literature contains innumerable studies of serum immunoglobulin levels and/or delayed hypersensitivity skin testing. In contrast, studies of the effects of nutritional deficiency on innate and adaptive
immune responses to infectious agents are rare, and the possibility
of nutritional supplementation improving responses to malaria,
HIV, and TB remains elusive. We already know that the incidence
of TB in the Western world decreased with improved nutrition
and sanitation, but we do not know whether such improvement

Figure 2
Differing pathophysiological responses to nutrient depletion. Nutritional
deficiencies can be categorized as Type I or Type II according to the
physiological responses of the body to dietary deficiency. In Type I
deficiencies, growth continues in children, eventually resulting in tissues becoming depleted in the nutrient, leading to metabolic dysfunction and consequent ill health. As the illness has characteristic signs
and symptoms, the deficient nutrient can be identified and remedied.
With Type II nutrient deficiency, the response is for the body to stop
growing and repairing tissue to conserve the nutrient, or even to break
down its own tissues to make the nutrient available. Other Type II nutrients are lost in the process. No characteristic signs or symptoms differentiate one Type II nutrient deficiency from another, and detecting
deficiency is complex. It is therefore almost impossible to determine
which nutrient is causing the growth failure.
1324
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Figure 3
Influence of malnutrition on hospital case fatality rates for various diseases. Malnutrition is rarely identified as a specific cause of mortality, but it is
an underlying contributory factor in at least one third of child deaths in developing countries. Depicted here are hospital case fatality rates from children admitted to Gambian hospitals with various primary diagnoses. The children analyzed were all malnourished, i.e., had low weight-for-height
(WFH). As shown, the extent of malnutrition (WFH z score < –4 being the most severely malnourished) correlates with the chance of an adverse
survival outcome in most diseases. WFH z score < –4, patients who are more than 4 standard deviations below the mean WFH; WFH z score = –3
to –4, patients who are 3–4 standard deviations below the mean WFH; WFH z score = –2 to –3, patients who are 2–3 standard deviations below
the mean WFH; WFH z score > –2, patients who are less than 2 standard deviations below the mean WFH. Data collated by Man et al. (12).

was secondary to changes in transmission or to improved nutrition, and indeed, whether these might have been interlinked (see
“Case study 3”). There are numerous other knowledge gaps. For
example, we need to know the influence of nutritional status on
recall (anamnestic) as well as primary immune responses. We need
to define in a more vigorous and rigorous way the relationships
between maternal nutrition, immunity, and transplacental transmission of immunoglobulins. We need to understand the biological mechanisms contributing to early-life nutritional programming
of immune function and survival. We need to know whether nutritional improvement of mucosal immunity is possible. We need to
know whether it is possible to modulate HIV transmission through
nutritional means. And we need to know if we can augment the efficacy of future vaccines by accompanying nutritive measures.
Host-pathogen competition for nutrients
Micronutrient deficiencies enhance susceptibility to infection, so
supplementation is frequently seen as beneficial in promoting resistance against infection. However, pathogenic microbes also require
micronutrients for their growth. Therefore, nutritional interventions
need critical evaluation to ensure that they do not benefit pathogens,
thus causing disease exacerbation, activation of latent infections, and
subsequently increased transmission rates (Figure 4).
Humans provide pathogens with habitats rich in essential nutrients. Consequently, a labile equilibrium is formed between host
The Journal of Clinical Investigation

and pathogen (13). Mechanisms to sequester nutritive resources
from pathogens are elementary parts of the mammalian host
defense system, and in response, microbes have evolved diverse
mechanisms for accessing nutrients from host sources. Although
likely to be a rather universal phenomenon, details of host-pathogen competition are only known for a few micronutrients and a
limited number of infections, and even for these exceptional cases,
understanding is far from complete.
Probably the best-characterized trace element in this respect is
iron, an essential factor for both host and pathogen (13). Microbes
have high-affinity, multicomponent iron-uptake systems to compete with the host and inhabit intracellular habitats to access
host iron reservoirs. Growth of many pathogenic bacteria, including species of Yersinia, Salmonella, Mycobacterium, Chlamydia, and
Legionella, depends on host-derived iron (14). Consequently, iron
overload in humans enhances susceptibility to these infections,
as well as to malaria and AIDS, although in all cases the reasons
for this effect are not well understood. This phenomenon has
important implications for prophylactic iron supplementation.
Clinically, anemia is considered a symptom requiring correction,
and population-wide supplementation has been recommended
based on some studies with beneficial outcome (15, 16). However, other studies revealed detrimental increases in the prevalence
and severity of diarrhea, malaria, yersiniosis, salmonellosis, and
TB (17, 18). Anemia can also be considered as an antimicrobial
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Figure 4
Optimizing nutritional status — a delicate and dynamic balance
between the host and its pathogens. The optimal level for any individual’s nutrient status is determined by a complex web of interacting
parameters including their genetic background, environmental exposures, and interactions with other nutrients. In developing countries,
and for certain nutrients (especially iron), host-pathogen competition
for the nutrient adds an extra layer of complexity. Attempts to increase
iron status conflict with the likelihood that excess iron might precipitate infections. The figure indicates that the optimum level (indicated
by the nadir in the curve) varies according to host genotype (e.g.,
resistance factors involved in nutrient handling) and the genotypes of
various pathogens (e.g., mechanisms of iron sequestration and consequent responses). By removing pathogen threats, as has largely
been achieved in developed countries, it becomes possible to safely
increase the optimum level of nutrient status with a view to improving
cognitive and developmental outcomes.

response, and it has been proposed that a degree of anemia might
represent an antiinfective adaptation (19). During inflammation,
hepcidin, the hormone-like peptide and global regulator of iron
homeostasis, causes anemia by decreasing intestinal iron uptake
and promoting its sequestration inside macrophages (20). Other
mechanisms also function to sequester iron from pathogens. For
instance, lactoferrin helps to reduce biofilm formation by Pseudomonas aeruginosa and controls growth of Mycobacterium tuberculosis
in iron-overloaded hosts (21, 22). Lipocalin-2 produced by epithelial cells and neutrophils binds bacterial-derived siderophores to
recapture iron (23). IFN-γ downregulates expression of the transferrin receptor to limit intracellular iron (24). In summary, iron
metabolism and bioavailability are tightly regulated, and increasing the free iron pool might correct anemia but at the same time
promote pathogen growth.
Pathogenic microbes often exploit the host for small organic molecules required for living, or as precursors for key biosynthetic pathways. There remains much to be learned about
these interactions. Some microorganisms have lost certain
biosynthetic genes, becoming auxotrophic and fully dependent on their (human) hosts. Chlamydia illustrates this point.
It is sometimes a tryptophan auxotroph, relying on the host
for this amino acid. As a host counter-strategy, IFN-γ induces
macrophages to express indoleamine 2,3-dioxygenase, which
catabolizes l-tryptophan to N-formylkynurenine, hence limiting its bioavailability and driving Chlamydia into latency (25).
Intriguingly, genetic variants in the tryptophan biosynthetic
pathway determine habitat specificity and distinguish genital
and ocular strains of Chlamydia (26). Arginine is a nonessential
amino acid that serves as a precursor for reactive nitrogen intermediates produced by macrophages. Arginine has therefore been
recommended as an “immunonutrient” (27). However, bacteria
such as biofilm-forming Staphylococcus aureus, intracellular Liste1326
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ria monocytogenes, and the intestinal parasite Giardia lamblia, all
of which can directly consume arginine using efficient transport systems, might be able to take advantage of supplementary
arginine (28, 29). Moreover, arginine-derived NO is consumed
in microaerobic respiration by Neisseria meningitidis and P. aeruginosa strains using NO reductases (30, 31). Similar issues are
likely to apply to many micronutrients including other amino
acids, zinc, copper, fatty acids, and cholesterol.
In conclusion, a deeper understanding is needed of the molecular basis of micronutrient effects on the innate and adaptive
immune systems of both model organisms and humans as well as
their exploitability by pathogens. This information should form
the foundation for hypothesis-based clinical trials that examine
the impact of micronutrient/trace element supplementation on
the host-pathogen relationship.
Understanding the contributions of our microbiome to
nutrition
Most of our interactions with microbes are mutually beneficial,
not pathogenic. We are born “germ-free” — a mixture of human
somatic and germ cells. Beginning at birth, microbes are added
to these starting materials. The process of colonization of our
body surfaces is complex, dynamic, and driven by mechanisms
that remain obscure. Nonetheless, recent work has emphasized
how acquisition of our microbiota is likely to reflect a confluence of “legacy effects” (the microbes we encounter following birth), and body “habitat effects” (how human genotypes,
immune systems, diets, and other factors define the chemical
climate of those parts of our body that become home to our
indigenous microbial communities) (32). By the time humans
reach adulthood, microbial cells (primarily bacteria) outnumber
human cells by as much as an order of magnitude. Most of these
bacteria reside in the distal gut, where their density approaches
one trillion organisms per milliliter of luminal contents. A few
notable facts have emerged from 16S rRNA–based surveys of the
distal gut microbiota of individuals living in Western societies
(33–35). There are marked interpersonal differences in community composition at the species level. Although representatives
of 10 of the 70 known bacterial divisions were identified in this
body habitat, more than 90% of all phylogenetic types (phylotypes) belonged to members of just two of these divisions — the
Bacteroidetes and the Firmicutes.
All of the genes embedded in the genomes of our microbial
partners together comprise our microbiome and may exceed the
number of genes in the Homo sapiens genome by several orders
of magnitude (36). It follows that individual physiologic phenotypes need to be considered as a coevolved blend of human and
microbial traits, and that understanding the underpinnings of
human biologic diversity means that we need to make a commitment to characterizing the shared, as well as individual, features
of our microbiomes. The Human Microbiome Project (HMP)
is a response to this quest for self knowledge. Its launch coincided with a changing focus in the field of microbiology — from
studying the properties and professions (niches) of single phylotypes under conditions that exist in the laboratory to studying
the operations of whole communities in their native habitats.
This more ecologic emphasis is now possible, in large part due
to the introduction of a new generation of massively parallel
DNA sequencers. The result is what has been called a new field
of science, metagenomics (36). Metagenomics embraces cultiva-
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tion-independent, genome-anchored characterizations of intact
microbial communities so that their assembly, composition, and
operation can be defined at the level of their genomes, transcriptomes, proteomes, and metabolomes. Metagenomics should provide answers to a number of key questions such as, Do the interpersonal differences in human microbiota defined by 16S rRNA
gene sequencing accurately portray the degree of diversity in the
microbiome? How are microbiomes shaped by host genotypes,
environmental exposures, including exposure to our mothers
and other family members, and lifestyles, including diet? And do
interpersonal differences in gut microbiome structure and function affect predisposition to malnutrition?
Some unsolved nutritional questions
The above discussion highlights some of the many areas in which
we believe that international nutrition research could benefit from
the infusion of fresh ideas and experimental rigor. To illustrate
these points, we describe four case studies that provide examples
of past deficiencies and future opportunities.
Case study 1: Universal vitamin A supplementation — success, but with
qualifications. The story of universal vitamin A supplementation for
children provides some good lessons of how, even in one of nutrition’s success stories, there could have been a more rigorous path
to success, and there remain a number of serious controversies
regarding mechanisms of action, optimal dosing regimens, and
safety. Following the introduction of policies on worldwide use
of iodized salt, the next micronutrient revolution involved vitamin A. In 1983, Sommer and colleagues reported the results of a
longitudinal natural history study conducted in Indonesia, where
they observed that preschool children with moderate vitamin A
deficiency (Bitot’s spots and night blindness) had an increased risk
of death (37). This epidemiologic association led to a controlled
clinical trial of vitamin A supplementation that was designed to
determine whether periodic high-dose vitamin A supplementation
could reduce child mortality (38). In 1987, the WHO and UNICEF
issued a joint recommendation (39) for high-dose vitamin A treatment of all children with measles from communities in which
vitamin A deficiency was a “recognized problem” or where the
case fatality rates for measles were 1% or greater, because measles
mortality was known to be strongly related to vitamin A status. In
1997, global advocacy by UNICEF encouraged community-based
vitamin A supplementation in developing countries, and now
most countries have adopted a national policy based on WHOrecommended dosing schedules (40).
Several lessons can be gleaned from this story. The proposal to
promote vitamin A supplementation as an important intervention initially generated controversy because the effects observed
seemed too good to be true, contradictory data were initially
reported (41), there was no clearly demonstrable impact on
the major causes of morbidity (42), and there was no plausible
mechanism to explain a reduction in mortality (43). In addition, just one group of investigators had generated the supporting data from large field studies. It was not until other groups
began to report similar results from different field settings, and
the results of carefully conducted clinical trials were published
supporting the effects of vitamin A, that supplementation was
broadly accepted as a major public health intervention (44, 45).
Moving forward to the present, we see that some of the impediments to moving from observation to intervention could perhaps have been more rapidly addressed by an integrated, interThe Journal of Clinical Investigation

disciplinary basic and clinical research program that focused
on how retinoids mediate host resistance to infection. Such an
approach could have provided earlier insights into plausible
mechanisms behind the large observed impact on mortality.
This might have led to targeted interventions, in which specific retinoids with defined effects on host defense mechanisms
might have been taken to clinical studies.
Although universal vitamin A supplementation is now accepted policy, the need for scientific clarity concerning its basic
mode of action has never been greater. There is fresh controversy concerning optimal timing and dose levels, with recent
suggestions that higher doses be given earlier in infancy (46)
lacking support from experimental trials (47, 48). Moreover,
there is evidence that vitamin A administration in the peripartum period has complex effects and, when taken daily, might
actually enhance mother-to-child transmission of HIV (49, 50).
There are also suggestions that vitamin A might have negative
interactions with some routine childhood vaccines, leading to
excess later mortality, especially in girls (51).
Case study 2: Iron — more harm than good in some children? Recommendations for universal iron supplementation in areas with
high rates of anemia, promoted for the best of motives by many
international agencies, have also highlighted the depths of our
collective ignorance about the benefits and possible harm of
iron. Iron is the most commonly prescribed therapeutic agent,
yet, as described above, it has potential toxic effects and may
promote growth of pathogenic microbes. Can we safely combat
anemia, and the other developmental deficits caused by iron
deficiency, through universal iron supplementation programs?
This question has been thrown into sharp relief by the premature termination by a data safety monitoring board of a very
large trial of iron supplementation in children in Pemba Island
after they detected a statistically significant increase in serious
adverse events (hospitalization and deaths) in the groups receiving iron (18). Since Pemba has holoendemic malaria, and since
a similar trial conducted in Nepal found no detrimental effect
of iron, it has been concluded that the result arose from a negative interaction between iron and malaria. Earlier data would
support this view, but it is by no means secure. Where do we go
from here? A subsample analysis from Pemba suggested that the
harmful effects were confined to children who were relatively
iron replete, and that supplementation of the most deficient
children would be safe.
The Pemba trial raises numerous questions at both the basic science and operational levels. What is the explanation of the adverse
outcomes? Is it really because iron has promoted malaria-related
morbidity? If so, does it promote malaria or malaria-related septicemia? Does this occur because supplementation involves nonphysiologic bolus doses of highly absorbable iron, overwhelming
the children’s iron-handling apparatus and resulting in non–transferrin-bound iron (NTBI) that is available to resident pathogens?
If so, can we design better formulations for the safer delivery of
iron? At the operational level, if we need to screen populations in
order to target supplementation, we need new portable and reliable methods for assessing iron status.
Case study 3: Nutrition and TB — more unknown than known. TB is
one of the most important human infectious diseases, with 1.7
million deaths and 8 million new cases annually. TB is generally
accepted as being closely linked to nutritional status, yet there
is a lamentable lack of a solid evidence base on which to incor-
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porate nutritional interventions into clinical practice or community preventative strategies. Several reports have suggested
protein energy malnutrition as a risk factor (52–54). Weight loss,
cachexia, and anemia caused by inflammatory responses to the
infection contribute further to the poor nutritional status of
patients with TB. Serum zinc concentrations are below those
of healthy controls, whereas copper concentrations are higher
(55, 56). However, these changes are characteristic of the APR,
and the studies fall foul of the reverse causality trap that can
only be circumvented by prospective nested case-control studies. Recent work has also revealed a potentially important connection between vitamin D and innate immunity in individuals
with TB. Vitamin D promotes expression of the anti-mycobacterial peptide, cathelicidin (57). Therefore, lower serum concentrations of vitamin D might contribute to diminished immunity against TB and provide a target for prophylactic as well as
therapeutic correction by dietary vitamin D supplementation.
Beyond these few glimpses into the likely influence of nutrition
on susceptibility to TB and disease progression, it is difficult to
find any other authoritative information.
Case study 4: Nutritional modulation of pathogenicity. Our final
case study illustrates how host nutritional status can affect the
basic biology of viruses. Beck and colleagues have demonstrated
that host deficiencies in the antioxidant nutrients selenium and
vitamin E allow mildly pathogenic strains of coxsackie viruses
and influenza viruses to mutate into virulent strains (reviewed
in ref. 58). The enhanced pathogenicity is genomically encoded
and hence maintained when passaged through nutrient-replete
animals. These findings raise numerous related questions. With
many pandemic viruses (e.g., HIV, influenza, Avian flu) originating in the poorest regions of developing countries, the question
arises as to whether nutrient deficiencies have created conditions
for the origination of novel pathogenic strains. There is an urgent
need to assess these processes in humans and to extend the original work on viral mutations to other microorganisms. Emergence
of exceptionally virulent drug-resistant strains of TB are assumed
to be driven by a combination of poorly implemented drug regimens and coinfection with HIV, which lowers immunosurveillance of emerging strains, but host malnutrition might play a
contributory role and merits investigation.
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The way forward
The usual arguments used to persuade leading scientists to
engage with issues affecting the developing world revolve around
the philanthropic principle. This also drives the strategic deployment of funds by many private, governmental, and international
agencies that are committed to sponsoring scientific programs
designed to address global health issues. We contend that as
global disease patterns increasingly merge, and because the basic
science underpinning many nutrient-disease interactions can
best be studied in “deplete” populations, there is an additional
motive of self-interest in engaging with the problems of the poorest peoples of the world.
The more fully we understand the mechanisms linking diet,
health, and disease, the more effective will be our ability to design
optimal nutrient interventions. At this time of remarkable and
explosive expansion in our ability to characterize our individual
human genomes, transcriptomes, proteomes, and metabolomes
as well as the impact of our environmental exposures and rapidly
changing lifestyles on their operations, we cannot justify empirical
guesses as to which nutrient interventions might benefit underprivileged children and adults whose lives are in jeopardy. The
individual challenges set out in The challenges represent only a few
among many areas in which international nutrition science could
be strengthened. A theme linking these challenges is that they
require a deeper incorporation of the concepts and experimental
techniques of multiple scientific disciplines into the field of nutrition. We hope that this brief and self-critical survey of our field will
stimulate interaction with investigators outside our field who are
supremely qualified to contribute these techniques and expertise
to studies of human nutrition.
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